Daiwa Securities Group’s ImmunityBio IBRX Stock Holding History
Bought
Maintained
Sold
Other funds holding IBRX
Daiwa Securities Group's IBRX Position: Q3 2026 in Review
Daiwa Securities Group sold out of ImmunityBio (IBRX) in Q3 2026, closing a stake of 86,500 shares — an estimated $757K sold.
Daiwa Securities Group first reported a position in IBRX in Q1 2018 and held it in 26 quarters. The position peaked at $1.53M in Q1 2026. 407 funds tracked by Wall St. Rank hold IBRX as of Q3 2026.
- Daiwa Securities Group reported no remaining ImmunityBio position as of Q3 2026 after selling out during the quarter.
- Daiwa Securities Group sold 86,500 ImmunityBio shares in Q3 2026, an estimated $757K.
- Daiwa Securities Group first reported a position in ImmunityBio in Q1 2018 and held it in 26 quarters.
- Daiwa Securities Group's ImmunityBio position peaked at $1.53M in Q1 2026.
- 407 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2026.
Based on Daiwa Securities Group's 13F filing for Q3 2026, filed 29 Oct 2026.